Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas
Objective To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas. Methods Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG‐PET/CT for disease staging prior to curative intent treatment. The m...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2014-04, Vol.109 (5), p.410-414 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 5 |
| container_start_page | 410 |
| container_title | Journal of surgical oncology |
| container_volume | 109 |
| creator | Skamene, Sonia R. Rakheja, Rajan Dalhstrom, Kristina R. Roberge, David Nahal, Ayoub Charest, Mathieu Turcotte, Robert Hickeson, Marc Freeman, Carolyn |
| description | Objective
To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas.
Methods
Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG‐PET/CT for disease staging prior to curative intent treatment. The maximum standardized uptake value (SUVmax) was measured for each primary tumor and correlated with outcome. Progression‐free survival and overall survival (OS) were analyzed using the Kaplan–Meier method.
Results
Soft‐tissue sarcomas were more frequent (68%) than bone (27%) or cartilage (5%) tumors. Median follow‐up was 33.2 months. 51% of patients progressed during the follow‐up interval and 38% died. SUVmax was dichotomized with a cut‐point of 10.3. Patients with SUVmax |
| doi_str_mv | 10.1002/jso.23523 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1509416702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3250911041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4263-752e5493a062520c315077474e8789467ef9bd88962ea93251e56cd92438d30f3</originalsourceid><addsrcrecordid>eNp1kcFuEzEQhi1ERUPgwAsgS1zgsI3XXtvrI0Sl0BaKlCCkXizHOwEH7zq1vZS8PS5Je0DiNJLnm08z_hF6UZOTmhA626RwQhmn7BGa1ESJShHVPkaT0qNVIxU5Rk9T2hBClBLNE3RMG1YTKtUE3XyCbFbBO4uNze6Xyzvcg0ljhA6HAX85Xc7mS2xDjOBNhoRvXf6BrXeDs8bjMGYb-vLsBrw12cGQD4h3_QqbocPfXew84GRiIU16ho7Wxid4fqhT9PX96XL-obq8Ovs4f3tZ2YYKVklOgTeKGSIop8SymhMpG9lAK1vVCAlrteraVgkKRjHKa-DCdqqc1naMrNkUvd57tzHcjJCy7l2y4L0ZIIxJF59qaiEJLeirf9BNGONQtrujWiE5LytN0Zs9ZWNIKcJab6PrTdzpmui7HHTJQf_NobAvD8Zx1UP3QN5_fAFme-DWedj936TPF1f3ymo_4VKG3w8TJv7UQjLJ9bfPZ_picfFucV1zfc3-AKHSn4E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1508675526</pqid></control><display><type>article</type><title>Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Skamene, Sonia R. ; Rakheja, Rajan ; Dalhstrom, Kristina R. ; Roberge, David ; Nahal, Ayoub ; Charest, Mathieu ; Turcotte, Robert ; Hickeson, Marc ; Freeman, Carolyn</creator><creatorcontrib>Skamene, Sonia R. ; Rakheja, Rajan ; Dalhstrom, Kristina R. ; Roberge, David ; Nahal, Ayoub ; Charest, Mathieu ; Turcotte, Robert ; Hickeson, Marc ; Freeman, Carolyn</creatorcontrib><description>Objective
To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas.
Methods
Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG‐PET/CT for disease staging prior to curative intent treatment. The maximum standardized uptake value (SUVmax) was measured for each primary tumor and correlated with outcome. Progression‐free survival and overall survival (OS) were analyzed using the Kaplan–Meier method.
Results
Soft‐tissue sarcomas were more frequent (68%) than bone (27%) or cartilage (5%) tumors. Median follow‐up was 33.2 months. 51% of patients progressed during the follow‐up interval and 38% died. SUVmax was dichotomized with a cut‐point of 10.3. Patients with SUVmax < 10.3 had better DFS and OS compared with patients with SUVmax ≥ 10.3 (P < 0.001 and P < 0.001, respectively [log‐rank test]). Multivariate analysis confirmed that even after adjusting for age, sex, site, tumor type (bone vs. soft‐tissue), grade, and stage; an SUVmax ≥ 10.3 correlated with a twofold risk of progression and 2.4 times greater risk of death (hazard ratio [HR] 2.0, 95% CI, 1.1–3.7, and HR, 2.4, 95% CI, 1.1–4.9).
Conclusion
SUVmax is an independent adverse prognostic factor for both progression and OS in patients with extremity sarcomas. J. Surg. Oncol. 2014 109:410–414. © 2013 Wiley Periodicals, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.23523</identifier><identifier>PMID: 24310279</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical outcomes ; Disease-Free Survival ; Extremities - pathology ; FDG-PET ; Female ; Fluorodeoxyglucose F18 - metabolism ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Positron-Emission Tomography - methods ; Predictive Value of Tests ; Prognosis ; Radiopharmaceuticals - metabolism ; Radiotherapy, Adjuvant ; sarcoma ; Sarcoma - diagnosis ; Sarcoma - metabolism ; Sarcoma - pathology ; Sarcoma - therapy ; SUVmax ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Journal of surgical oncology, 2014-04, Vol.109 (5), p.410-414</ispartof><rights>2013 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4263-752e5493a062520c315077474e8789467ef9bd88962ea93251e56cd92438d30f3</citedby><cites>FETCH-LOGICAL-c4263-752e5493a062520c315077474e8789467ef9bd88962ea93251e56cd92438d30f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.23523$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.23523$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24310279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skamene, Sonia R.</creatorcontrib><creatorcontrib>Rakheja, Rajan</creatorcontrib><creatorcontrib>Dalhstrom, Kristina R.</creatorcontrib><creatorcontrib>Roberge, David</creatorcontrib><creatorcontrib>Nahal, Ayoub</creatorcontrib><creatorcontrib>Charest, Mathieu</creatorcontrib><creatorcontrib>Turcotte, Robert</creatorcontrib><creatorcontrib>Hickeson, Marc</creatorcontrib><creatorcontrib>Freeman, Carolyn</creatorcontrib><title>Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Objective
To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas.
Methods
Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG‐PET/CT for disease staging prior to curative intent treatment. The maximum standardized uptake value (SUVmax) was measured for each primary tumor and correlated with outcome. Progression‐free survival and overall survival (OS) were analyzed using the Kaplan–Meier method.
Results
Soft‐tissue sarcomas were more frequent (68%) than bone (27%) or cartilage (5%) tumors. Median follow‐up was 33.2 months. 51% of patients progressed during the follow‐up interval and 38% died. SUVmax was dichotomized with a cut‐point of 10.3. Patients with SUVmax < 10.3 had better DFS and OS compared with patients with SUVmax ≥ 10.3 (P < 0.001 and P < 0.001, respectively [log‐rank test]). Multivariate analysis confirmed that even after adjusting for age, sex, site, tumor type (bone vs. soft‐tissue), grade, and stage; an SUVmax ≥ 10.3 correlated with a twofold risk of progression and 2.4 times greater risk of death (hazard ratio [HR] 2.0, 95% CI, 1.1–3.7, and HR, 2.4, 95% CI, 1.1–4.9).
Conclusion
SUVmax is an independent adverse prognostic factor for both progression and OS in patients with extremity sarcomas. J. Surg. Oncol. 2014 109:410–414. © 2013 Wiley Periodicals, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical outcomes</subject><subject>Disease-Free Survival</subject><subject>Extremities - pathology</subject><subject>FDG-PET</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - metabolism</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Positron-Emission Tomography - methods</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals - metabolism</subject><subject>Radiotherapy, Adjuvant</subject><subject>sarcoma</subject><subject>Sarcoma - diagnosis</subject><subject>Sarcoma - metabolism</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - therapy</subject><subject>SUVmax</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFuEzEQhi1ERUPgwAsgS1zgsI3XXtvrI0Sl0BaKlCCkXizHOwEH7zq1vZS8PS5Je0DiNJLnm08z_hF6UZOTmhA626RwQhmn7BGa1ESJShHVPkaT0qNVIxU5Rk9T2hBClBLNE3RMG1YTKtUE3XyCbFbBO4uNze6Xyzvcg0ljhA6HAX85Xc7mS2xDjOBNhoRvXf6BrXeDs8bjMGYb-vLsBrw12cGQD4h3_QqbocPfXew84GRiIU16ho7Wxid4fqhT9PX96XL-obq8Ovs4f3tZ2YYKVklOgTeKGSIop8SymhMpG9lAK1vVCAlrteraVgkKRjHKa-DCdqqc1naMrNkUvd57tzHcjJCy7l2y4L0ZIIxJF59qaiEJLeirf9BNGONQtrujWiE5LytN0Zs9ZWNIKcJab6PrTdzpmui7HHTJQf_NobAvD8Zx1UP3QN5_fAFme-DWedj936TPF1f3ymo_4VKG3w8TJv7UQjLJ9bfPZ_picfFucV1zfc3-AKHSn4E</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Skamene, Sonia R.</creator><creator>Rakheja, Rajan</creator><creator>Dalhstrom, Kristina R.</creator><creator>Roberge, David</creator><creator>Nahal, Ayoub</creator><creator>Charest, Mathieu</creator><creator>Turcotte, Robert</creator><creator>Hickeson, Marc</creator><creator>Freeman, Carolyn</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas</title><author>Skamene, Sonia R. ; Rakheja, Rajan ; Dalhstrom, Kristina R. ; Roberge, David ; Nahal, Ayoub ; Charest, Mathieu ; Turcotte, Robert ; Hickeson, Marc ; Freeman, Carolyn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4263-752e5493a062520c315077474e8789467ef9bd88962ea93251e56cd92438d30f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical outcomes</topic><topic>Disease-Free Survival</topic><topic>Extremities - pathology</topic><topic>FDG-PET</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - metabolism</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Positron-Emission Tomography - methods</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals - metabolism</topic><topic>Radiotherapy, Adjuvant</topic><topic>sarcoma</topic><topic>Sarcoma - diagnosis</topic><topic>Sarcoma - metabolism</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - therapy</topic><topic>SUVmax</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skamene, Sonia R.</creatorcontrib><creatorcontrib>Rakheja, Rajan</creatorcontrib><creatorcontrib>Dalhstrom, Kristina R.</creatorcontrib><creatorcontrib>Roberge, David</creatorcontrib><creatorcontrib>Nahal, Ayoub</creatorcontrib><creatorcontrib>Charest, Mathieu</creatorcontrib><creatorcontrib>Turcotte, Robert</creatorcontrib><creatorcontrib>Hickeson, Marc</creatorcontrib><creatorcontrib>Freeman, Carolyn</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skamene, Sonia R.</au><au>Rakheja, Rajan</au><au>Dalhstrom, Kristina R.</au><au>Roberge, David</au><au>Nahal, Ayoub</au><au>Charest, Mathieu</au><au>Turcotte, Robert</au><au>Hickeson, Marc</au><au>Freeman, Carolyn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>109</volume><issue>5</issue><spage>410</spage><epage>414</epage><pages>410-414</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Objective
To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas.
Methods
Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG‐PET/CT for disease staging prior to curative intent treatment. The maximum standardized uptake value (SUVmax) was measured for each primary tumor and correlated with outcome. Progression‐free survival and overall survival (OS) were analyzed using the Kaplan–Meier method.
Results
Soft‐tissue sarcomas were more frequent (68%) than bone (27%) or cartilage (5%) tumors. Median follow‐up was 33.2 months. 51% of patients progressed during the follow‐up interval and 38% died. SUVmax was dichotomized with a cut‐point of 10.3. Patients with SUVmax < 10.3 had better DFS and OS compared with patients with SUVmax ≥ 10.3 (P < 0.001 and P < 0.001, respectively [log‐rank test]). Multivariate analysis confirmed that even after adjusting for age, sex, site, tumor type (bone vs. soft‐tissue), grade, and stage; an SUVmax ≥ 10.3 correlated with a twofold risk of progression and 2.4 times greater risk of death (hazard ratio [HR] 2.0, 95% CI, 1.1–3.7, and HR, 2.4, 95% CI, 1.1–4.9).
Conclusion
SUVmax is an independent adverse prognostic factor for both progression and OS in patients with extremity sarcomas. J. Surg. Oncol. 2014 109:410–414. © 2013 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24310279</pmid><doi>10.1002/jso.23523</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2014-04, Vol.109 (5), p.410-414 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1509416702 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Chemotherapy Chemotherapy, Adjuvant Clinical outcomes Disease-Free Survival Extremities - pathology FDG-PET Female Fluorodeoxyglucose F18 - metabolism Follow-Up Studies Humans Kaplan-Meier Estimate Male Middle Aged Multivariate Analysis Neoplasm Staging Positron-Emission Tomography - methods Predictive Value of Tests Prognosis Radiopharmaceuticals - metabolism Radiotherapy, Adjuvant sarcoma Sarcoma - diagnosis Sarcoma - metabolism Sarcoma - pathology Sarcoma - therapy SUVmax Tomography, X-Ray Computed Treatment Outcome |
| title | Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A23%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20activity%20measured%20on%20PET/CT%20correlates%20with%20clinical%20outcomes%20in%20patients%20with%20limb%20and%20girdle%20sarcomas&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Skamene,%20Sonia%20R.&rft.date=2014-04-01&rft.volume=109&rft.issue=5&rft.spage=410&rft.epage=414&rft.pages=410-414&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.23523&rft_dat=%3Cproquest_cross%3E3250911041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1508675526&rft_id=info:pmid/24310279&rfr_iscdi=true |